SOURCE: Threshold Pharmaceuticals
SOUTH SAN FRANCISCO, CA--(Marketwire - Sep 19, 2012) - Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Charles P. Hart, Ph.D., Threshold's Vice President of Biology, will present an overview of the company's targeted tumor hypoxia platform at BIOX, Noble Financial Capital Markets' Life Sciences Exposition, to be held at the University of Connecticut, Stamford Campus on September 24-25, 2012.
Dr. Hart's presentation will focus on targeting tumor hypoxia for the discovery and development of novel cancer therapies. The presentation will also highlight scientific rationale for evaluation of the company's lead hypoxia-targeted drug, TH-302, in multiple phase 1 studies in combination with antiangiogenic therapies for the treatment of various cancers.
Following the event, a webcast of the presentation will be available on September 27, 2012, under Webcasts in the Investors section of www.thresholdpharm.com. A replay of the presentation will be archived on the site for 30 days.
About Threshold Pharmaceuticals
Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors as well as the bone marrows of some hematologic malignancies. This approach offers broad potential to treat a variety of cancers. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs. For additional information, please visit our website (www.thresholdpharm.com).
Except for statements of historical fact, the statements in this press release are forward-looking statements, including statements regarding Threshold's product candidates, and their potential therapeutic uses and benefits. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, Threshold's ability to enroll or complete its anticipated clinical trials, the time and expense required to conduct such clinical trials and analyze data, issues arising in the regulatory or manufacturing process and the results of such clinical trials (including product safety issues and efficacy results). Further information regarding these and other risks is included under the heading "Risk Factors" in Threshold's Quarterly Report on Form 10-Q, which has been filed with the Securities and Exchange Commission on August 6, 2012 and is available from the SEC's website (www.sec.gov) and on our website (www.thresholdpharm.com) under the heading "Investors." We undertake no duty to update any forward-looking statement made in this news release.